Entia Biosciences(OTC) ERGO

Entia Biosciences, Inc. is a healthcare company focused on developing, producing, and distributing dietary supplements, nutraceuticals, and medical food products. The company is known for its innovative product, ErgoD2, which aims to improve iron homeostasis and address iron-related disorders.

Products and Services

• ErgoD2, a pharmaceutical-grade organic compound for iron-related disorders
• Natural formulations for medical food, nutraceuticals, and cosmetics
• Beauty products marketed under the GROH brand name

Growth Outlook

• Increasing demand for dietary supplements and nutraceuticals in the U.S. market
• Expansion of e-commerce channels for direct consumer marketing
• Potential for new product development in iron-related health solutions

Financial Highlights

• Recent quarterly revenue of 45,986, showing growth potential
• Gross profit margin of 77.99% indicates strong product profitability
• Operating cash flow trends suggest ongoing investment in growth initiatives

Entia Biosciences, Inc. operates in the medical and pharmaceutical industry, with a focus on innovative health solutions. The company has developed ErgoD2, which targets iron-related health issues, including anemia and chronic kidney disease. This product positions Entia as a key player in a growing market, driven by increasing consumer awareness of health and wellness. The growth outlook for Entia is promising, with a notable increase in demand for dietary supplements and nutraceuticals. The company's strategy to expand its e-commerce presence allows for direct consumer engagement, enhancing brand visibility and sales potential. Additionally, ongoing research and development efforts may lead to new product offerings, further solidifying its market position. Financially, the company reported a recent quarterly revenue of 45,986, reflecting its ability to generate income despite challenges. The gross profit margin of 77.99% highlights the profitability of its products, indicating effective cost management and pricing strategies. Furthermore, trends in operating cash flow suggest that Entia is committed to investing in its growth initiatives, which may lead to improved financial performance in the future. Overall, Entia Biosciences, Inc. presents an intriguing opportunity for investors interested in the healthcare sector, particularly in the growing field of dietary supplements and nutraceuticals.